Drug Trial Radar · NCT02983578
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
39
Actual
Start
Mar 2, 2017
Primary completion
Aug 30, 2025
Study completion Aug 30, 2025
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); AstraZeneca
- First posted
- Dec 6, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well danvatirsen and durvalumab work in treating patients with pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer that has spread to other places in the body and does not respond to treatment. Danvatirsen may be used to block the production of proteins needed for tumor cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving danvatirsen and durvalumab may work better at treating pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer.
Conditions
- Advanced Colorectal Carcinoma
- Advanced Lung Non-Small Cell Carcinoma
- Lung Non-Small Cell Carcinoma
- Mismatch Repair Deficiency
- Refractory Colorectal Carcinoma
- Refractory Lung Carcinoma
- Refractory Pancreatic Carcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IIIA Colorectal Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Colorectal Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Colorectal Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8
Interventions
DanvatirsenDrug
Given IV
DurvalumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs), serious AEsTime frame: Up to 4 years
- Physiological parameters (Laboratory evaluations)Time frame: Up to 4 years
- Incidence of treatment-emergent AEs (TEAEs), SAEs and death(s)Time frame: Up to 4 years
- PD-L1 expressionTime frame: Up to 4 years
- Phosphorylated or total STAT3 expression levelsTime frame: Up to 4 years
- Characterization of immune infiltratesTime frame: Up to 4 years
- Quantification and characterization of CD8 staining patternTime frame: Up to 4 years
- PD-L1 protein levels in the membrane of circulating tumor cellsTime frame: Baseline up to 4 years
- Physiological parametersTime frame: Up to 4 years
- Physical ExaminationsTime frame: Up to 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M D Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.